TABLE 3.
Multivariable logistic regression analysis for 1‐, 3‐, and 5‐year mortality after esophageal cancer surgery
| 1‐year mortality | 3‐year mortality | 5‐year mortality | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n/N (%) | OR (95% CI) | p | n/N (%) | OR (95% CI) | p | n/N (%) | OR (95% CI) | p | |
| Case‐volume | |||||||||
| High‐volume (>48 cases/year) | 729/5421 (13.4%) | 1 | 1614/4569 (35.3%) | 1 | 1643/3730 (44%) | 1 | |||
| Medium‐volume (12–48 cases/year) | 498/3129 (15.9%) | 1.35 (1.19–1.54) | <0.001 | 1114/2649 (42.1%) | 1.43 (1.29–1.59) | <0.001 | 1144/2143 (53.4%) | 1.55 (1.38–1.74) | <0.001 |
| Low‐volume (<12 cases/year) | 398/2116 (18.8%) | 1.63 (1.41–1.88) | <0.001 | 816/1750 (46.6%) | 1.67 (1.48–1.88) | <0.001 | 847/1428 (59.3%) | 1.94 (1.70–2.21) | <0.001 |
| Age | |||||||||
| 19–60 | 416/3109 (13.4%) | 1 | 947/2638 (35.9%) | 1 | 952/2160 (44.1%) | 1 | |||
| 61–70 | 651/4622 (14.1%) | 1.08 (0.94–1.24) | 0.289 | 1516/3903 (38.8%) | 1.16 (1.04–1.29) | 0.007 | 1613/3235 (49.9%) | 1.27 (1.14–1.43) | <0.001 |
| 71–80 | 491/2741 (17.9%) | 1.62 (1.39–1.88) | <0.001 | 988/2281 (43.3%) | 1.55 (1.38–1.76) | <0.001 | 992/1798 (55.2%) | 1.74 (1.52–1.99) | <0.001 |
| ≥81 | 67/194 (34.5%) | 4.31 (3.11–5.96) | <0.001 | 93/146 (63.7%) | 3.89 (2.72–5.56) | <0.001 | 77/108 (71.3%) | 3.68 (2.38–5.69) | <0.001 |
| Sex | |||||||||
| Female | 94/816 (11.5%) | 1 | 191/647 (29.5%) | 1 | 185/506 (36.6%) | 1 | |||
| Male | 1531/9850 (15.5%) | 1.34 (1.07–1.68) | 0.011 | 3353/8321 (40.3%) | 1.58 (1.32–1.89) | <0.001 | 3449/6795 (50.8%) | 1.76 (1.45–2.13) | <0.001 |
| Comorbidities | |||||||||
| Hypertension | 682/4378 (15.6%) | 0.96 (0.84–1.08) | 0.465 | 1420/3589 (39.6%) | 0.94 (0.85–1.04) | 0.213 | 1414/2824 (50.1%) | 0.95 (0.86–1.06) | 0.382 |
| Diabetes mellitus | 461/2757 (16.7%) | 1.13 (0.99–1.28) | 0.064 | 928/2248 (41.3%) | 1.09 (0.98–1.22) | 0.103 | 910/1787 (50.9%) | 1.03 (0.92–1.16) | 0.636 |
| Coronary artery disease | 236/1505 (15.7%) | 0.99 (0.84–1.16) | 0.893 | 507/1268 (40.0%) | 1.02 (0.90–1.16) | 0.769 | 518/1036 (50%) | 0.99 (0.86–1.14) | 0.909 |
| Chronic obstructive pulmonary disease | 168/920 (18.3%) | 1.23 (1.02–1.47) | 0.028 | 323/793 (40.7%) | 1.00 (0.86–1.17) | 0.997 | 343/659 (52%) | 1.05 (0.89–1.24) | 0.555 |
| Chronic liver disease | 574/3741 (15.3%) | 0.98 (0.87–1.10) | 0.737 | 1228/3103 (39.6%) | 0.98 (0.89–1.08) | 0.670 | 1261/2508 (50.3%) | 1.00 (0.90–1.11) | 0.975 |
| Chronic kidney disease | 29/135 (21.5%) | 1.44 (0.93–2.22) | 0.099 | 48/98 (49.0%) | 1.43 (0.94–2.17) | 0.091 | 36/58 (62.1%) | 1.72 (0.99–2.99) | 0.056 |
| Cerebrovascular disease | 149/902 (16.5%) | 1.09 (0.89–1.32) | 0.406 | 301/735 (41.0%) | 1.07 (0.91–1.26) | 0.397 | 291/540 (53.9%) | 1.17 (0.97–1.41) | 0.093 |
| Adjuvant therapy | |||||||||
| Neoadjuvant chemotherapy | 822/6006 (13.7%) | 1 | 1856/5051 (36.7%) | 1 | 1899/4077 (46.6%) | 1 | |||
| No neoadjuvant therapy | 497/3241 (15.3%) | 1.28 (1.12–1.47) | <0.001 | 1195/2870 (41.6%) | 1.33 (1.20–1.48) | <0.001 | 1298/2459 (52.8%) | 1.30 (1.16–1.46) | <0.001 |
| Neoadjuvant chemotherapy with radiotherapy | 306/1419 (21.6%) | 2.94 (2.57–3.36) | <0.001 | 493/1047 (47.1%) | 2.90 (2.58–3.26) | <0.001 | 437/765 (57.1%) | 2.85 (2.50–3.26) | <0.001 |
| Surgery year | |||||||||
| 2004–2010 | 806/4739 (17.0%) | 1.43 (1.28–1.60) | <0.001 | 1997/4739 (42.1%) | 1.35 (1.23–1.47) | <0.001 | 2470/4739 (39.8%) | 1.36 (1.23–1.51) | <0.001 |
| 2011–2017 | 819/5927 (13.8%) | 1 | 1547/4229 (36.6%) | 1 | 1989/3165 (62.8%) | 1 | |||
Abbreviations: CI, confidence interval; OR, odds ratio.